Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer

Stephen D.W. Beck, Richard S. Foster, Richard Bihrle, Lawrence H. Einhorn, John P. Donohue

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Increased serum tumor markers after cisplatin-based chemotherapy have usually been considered a contraindication to surgery because of the presence of persistent active germ cell elements. However, a select population of patients with elevated serum tumor markers have undergone post-chemotherapy retroperitoneal lymph node dissection (RPLND) with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Long-term survival was observed in 50% of patients. Residual germ cell cancer was identified in 50% of patients, with a third alive at 5 years with no observed benefit from adjuvant chemotherapy. Select patients with increased tumor markers after chemotherapy are cured with surgery.

Original languageEnglish (US)
Pages (from-to)423-430
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume23
Issue number6
DOIs
StatePublished - Nov 1 2005

    Fingerprint

Keywords

  • RPLND
  • Serum tumor markers
  • Testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this